Wed, Nov 26, 2014, 5:33 AM EST - U.S. Markets open in 3 hrs 57 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • zake1 zake1 Jan 5, 2013 1:04 PM Flag

    This from the New York Times

    The New York TimesSaturday January 5, 2013 7:31 AM

    Comments: 0





    A closely watched experimental drug to treat Lou Gehrig’s disease failed to work in a late-stage clinical trial, the drug’s developer, Biogen Idec, said, disappointing medical experts who had hoped that it might be a useful tool against the poorly understood and fatal illness.

    The company said Thursday that it would discontinue work on the drug.

    Biogen said the drug was not effective in either slowing the loss of muscular function or prolonging the lives of people with the disease, formally known as amyotrophic lateral sclerosis, or ALS.

    There also were no signs that the drug, dexpramipexole, worked in any subgroup of patients, Biogen said.

    “As a physician who has treated people with ALS, I hoped with all my heart for a different outcome,” Dr. Douglas Kerr, director of neurodegeneration clinical research at Biogen, said in a statement.

    ALS, which attacks the nerves that control muscles, causes gradual paralysis and typically results in death within a few years of diagnosis.

    Only one drug has been approved to treat it, Rilutek, made by Sanofi, which doctors say is only moderately effective. Many other drugs have failed in clinical trials, in part because scientists do not understand the cause of ALS.

    While expectations were not high that dexpramipexole would succeed in its Phase 3 trial, there was more optimism than for many previous ALS drugs, given what some doctors viewed as strong results in a smaller, Phase 2 trial.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The only hope for ALS patients now is in stem cells trials and research. As I followed Iplex years ago, now I follow Neuralstem (Nyse: CUR) which the next 8th of January will give un update on 18 ALS patients. At least one of them (Ted Harada) has recieved a strong improvement from stem cells injections. Why not hoping to combine Iplex with stem cells treatement to arrive finally to defeat this horrible desease?

      Sentiment: Buy

    • The company said it would continue to work on potential treatments for the disease.

 
INSM
14.24+0.04(+0.28%)Nov 25 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.